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Background: To investigate the prognostic signiﬁcance of the number of lymph nodes removed in
colorectal cancer (CRC) patients with no metastatic lymph node. Patients and methods: The clinico-
pathological data of 461 CRC patients was analyzed. In order to compare the survival of patients who had
fewer lymph nodes removed versus the survival of patients who had 1e3 metastatic lymph node(s), a
separate group of 74 N1 disease patients were also included in the study. All patient data were collected
prospectively. KaplaneMeier method was used for calculation and plotting of the survival curves of the
patient groups, and log-rank test was used for the comparison of the survival curves. Results: Cancer-
speciﬁc survival (CSS) rates of patients who had 1e7 lymph node(s) and 8e11 lymph nodes removed
were signiﬁcantly worse than those who had 12 or more lymph nodes removed (p ¼ 0.006 and p ¼ 0.037,
respectively), while CSS was not signiﬁcantly different between those who had 1e7 versus 8e11 lymph
node(s) removed (p ¼ 0.647); this grouping had independent prognostic signiﬁcance in Cox analysis
(p ¼ 0.006). CSS of patients with N1 disease was not signiﬁcantly different from those who had 1e7 and
8e11 lymph node(s) removed (p ¼ 0.312 and p ¼ 0.165, respectively), while it was signiﬁcantly worse
than CSS of patients who had 12 or more lymph nodes removed (p ¼ 0.001). Conclusion: In colorectal
cancer patients whose removed lymph nodes are non-metastatic, removal of at least 12 lymph nodes will
determine the lymph node status reliably.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
In patients with colorectal cancer who undergo curative resec-
tion in the absence of distant metastasis, regional lymph node
status is one of the most important prognostic factors. The number
of lymph nodes that need to be removed for classiﬁcation of nodal
disease was indicated as 7e14 in the 6th edition [1] and 10e14 in
the 7th edition [2] of the American Joint Committee on Cancer
(AJCC)/International Union Against Cancer (UICC) tumor (T)- node
(N)- metastasis (M) classiﬁcation; however, theseker).
by Elsevier Ltd. All rights reservedrecommendations are not followed to determine node-negative
disease or to group metastatic lymph node numbers, and lymph
node classiﬁcation is performed despite the lower number of
lymph nodes removed. In a commentary on TNM classiﬁcation,
authors indicated that at least 12 lymph nodes need to be removed
[3]. College of American Pathologists Consensus Statement [4] and
NCCN guideline [5] also recommend the removal of at least 12
lymph nodes.
In this study, we investigated the prognostic signiﬁcance of the
number of lymph nodes removed in colorectal cancer patients with
no metastatic lymph node, and we compared the prognosis of pa-
tients who had fewer lymph nodes removed with the prognosis of
patients who had 1e3 metastatic lymph node(s) (N1 disease)..
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2.1. Patients
We assessed node-negative colorectal cancer patients (at least
one lymph node removed) with no distant metastasis, with no past
or concurrent malignancy otherwise, who underwent curative
resection (R0) between January 1993 and December 2004 in SB
Okmeydanı Training and Research Hospital. Excluded were 25 pa-
tients who received neoadjuvant therapy, 12 patients with syn-
chronous colorectal cancer, 8 patients with familial adenomatous
polyposis coli, and 34 patients who died in early postoperative
period due to complications. A total of 461 patients were eligible for
this study. Histologic grade was categorized as low grade (well and
moderately differentiated) and high grade (poorly differentiated,
undifferentiated, mucinous, signet ring cell). A 5-ﬂuorouracyl based
regiment was used in all patients receiving chemotherapy. All pa-
tient's clinicopathological data were collected prospectively.
In order to compare the survival of patients who had fewer
lymph nodes removed versus the survival of patients who had 1e3
metastatic lymph node(s), a separate group of 74 N1 disease pa-
tients who had at least 12 lymph nodes removed and fulﬁlling the
above inclusion criteria were also included in the study.
Survival data of the patients were obtained by phone interviews
with the patient or patient's relatives and from the records of our
hospital's Oncology Department. The endpoint of the study was
patient death. Cancer-speciﬁc survival (CSS) time was regarded as
the time interval between surgery and patient death due to disease
recurrence. In 16 patients who developed a second malignancy, the
diagnosis date of the second malignancy was considered as the lastTable 1
Cancer-speciﬁc survival rates of the patients according to clinicopathologic features.
Feature No. of
patients
No. of
events
Percent of
cancer-free
patients
p
Gender 0.670
Female 199 61 69.3
Male 262 84 67.9
Age, years 0.285
<65 298 92 69.1
65 163 53 67.5
Tumor site 0.175
Colon 256 74 71.1
Rectum 205 71 65.4
Tumor size, cm 0.365
5 169 49 71.0
>5 292 96 67.1
Histological grade 0.920
Low grade 406 127 68.7
High grade 55 18 67.3
T stage 0.089
T1eT2 119 30 74.8
T3eT4 342 115 66.4
LN removed (grouping A) 0.014
1e7 128 50 60.9
8e11 108 39 63.9
12 225 56 75.1
LN removed (grouping B) 0.004
1e11 236 89 62.3
12 225 56 75.1
Surgery 0.497
Elective 405 126 68.9
Urgent 56 19 66.1
Adjuvant chemotherapy 0.090
Yes 317 94 70.3
No 144 51 64.6
LN: lymph node.follow-up date. In 74 patients whose death was unrelated to cancer,
the date of death was considered as the last follow-up date.
2.2. Statistics
The CSS curves were calculated and plotted using the
KaplaneMeier method and the two-sided log-rank test was used
for the comparison of the survival curves of the patient groups. The
relative importance of the prognostic features was investigated
using the Cox proportional hazards model. p values less than 0.05
were considered to be statistically signiﬁcant. All statistical ana-
lyses were performed using SPSS version 17.0 (SPSS, Inc., Chicago,
IL).
3. Results
In patients with node-negative colorectal cancer the median
number of lymph nodes removed was 11 (mean 12.3, range 1e50).
One hundred and forty-ﬁve patients died because of colorectal
cancer. Mean follow-up period for the surviving patients was 130.1
months. Survival analyses were conducted for two patient group-
ings (A, B) according to the number of lymph nodes removed. CSS
rates according to clinicopathologic features and these patient
groupings are shown in Table 1. Of 74 patients with N1 disease 42
(56.8%) were cancer-free; mean follow-up period for the surviving
patients was 117.9 months. As shown in Table 1 and Fig. 1, in
grouping A, CSS rates of patients who had 1e7 lymph node(s) and
8e11 lymph nodes removed were signiﬁcantly worse than those
who had 12 or more lymph nodes removed (p ¼ 0.006 and
p ¼ 0.037, respectively), while CSS was not signiﬁcantly different
between those who had 1e7 versus 8e11 lymph node(s) removed
(p ¼ 0.647); this grouping had independent prognostic signiﬁcance
in Cox analysis (p ¼ 0.006) (Table 2). Also as shown in Fig. 1, CSS ofFig. 1. Cancer-speciﬁc survival rates of the patients with non-metastatic lymph
node(s) (grouping A) and N1 disease. One-7 vs 12 lymph node(s) (LN) removed,
p ¼ 0.006; 8e11 vs 12 LN removed, p ¼ 0.037; 1e7 vs 8e11 LN removed, p ¼ 0.647;
N1 disease vs 1e7 LN removed, p ¼ 0.312; N1 disease vs 8e11 LN removed, p ¼ 0.165;
N1 disease vs 12 LN removed, p ¼ 0.001.
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who had 1e7 and 8e11 lymph node(s) removed (p ¼ 0.312 and
p¼ 0.165, respectively), while it was signiﬁcantly worse than CSS of
patients who had 12 or more lymph nodes removed (p ¼ 0.001).
In grouping B which was formed according to the recommen-
dation of removing at least 12 nodes to describe the lymph node
status as negative, CSS of patients who had 12 ormore lymph nodes
removed was signiﬁcantly better than those who had 1e11 lymph
node(s) removed (p ¼ 0.004) (Table 1) (Fig. 2). This grouping
showed independent prognostic signiﬁcance in multivariate anal-
ysis (p ¼ 0.004) (Table 3).Fig. 2. Cancer-speciﬁc survival rates of the patients with non-metastatic lymph
node(s) (grouping B). One-11 vs 12 lymph node(s) (LN) removed, p ¼ 0.004.4. Discussion
In colorectal cancer, the least number of lymph nodes to be
removed to reliably deﬁne the lymph node status as negative (non-
metastatic) is controversial. The latest version of AJCC/UICC TNM
classiﬁcation stated that “It is important to obtain at least 10e14
lymph nodes in radical colon and rectum resections in patients
without neoadjuvant therapy. A pN0 determination is assigned
when these nodes are histologically negative, even though fewer
than the recommended number of nodes has been analyzed.” [2].
In our series of colorectal cancer patients with no metastasis
detected in the removed lymph nodes, patients with 1e7 and 8e11
lymph nodes removed had signiﬁcantly worse CSS than patients
with 12 or more lymph nodes removed. CSS did not differ signiﬁ-
cantly between patients with 1e7 lymph node(s) removed and
patients with 8e11 lymph nodes removed; survival rates of both
groups were similar to the survival rate of patients with N1 disease.
Based on this data we performed a survival analysis assuming the
least number of lymph nodes to be removed as 12 to deﬁne the
lymph node status as “negative”, andwe determined that the CSS of
patients with 1e11 lymph nodes removed was signiﬁcantly worse
than the CSS of patients with 12 or more lymph nodes removed.Table 2
Cox proportional hazards model analysis of the clinicopathologic features and nodal
grouping A.
Feature Relative risk 95% CI p
Gender 0.755
Female 1.00
Male 1.05 0.75e1.47
Age, years 0.984
<65 1.00
65 1.00 0.69e1.45
Tumor site 0.205
Colon 1.00
Rectum 1.26 0.88e1.80
Tumor size, cm 0.119
5 1.00
>5 1.34 0.92e1.94
Histological grade 0.871
Low grade 1.00
High grade 1.04 0.63e1.73
T stage 0.004
T1eT2 1.00
T3eT4 2.02 1.25e3.25
LN removed (grouping A) 0.006
1e7 1.00
8e11 0.76 0.49e1.17
12 0.52 0.34e0.77
Surgery 0.560
Elective 1.00
Urgent 1.16 0.69e1.97
Adjuvant chemotherapy 0.009
Yes 1.00
No 1.74 1.15e2.63
CI: conﬁdence interval; LN: lymph node.These two node groupings had independent prognostic signiﬁ-
cance in the multivariate analysis.
In clinical studies various numbers were reported as the
threshold for the least number of lymph nodes to be removed to
safely determine the lymph node status and provide survival
advantage. In each study, survival of patients with node negativeTable 3
Cox proportional hazards model analysis of the clinicopathologic features and nodal
grouping B.
Feature Relative risk 95% CI p
Gender 0.709
Female 1.00
Male 1.06 0.76e1.49
Age, years 0.985
<65 1.00
65 0.99 0.69e1.43
Tumor site 0.219
Colon 1.00
Rectum 1.25 0.87e1.79
Tumor size, cm 0.145
5 1.00
>5 1.31 0.91e1.90
Histological grade 0.920
Low grade 1.00
High grade 1.02 0.62e1.70
T stage 0.006
T1eT2 1.00
T3eT4 1.94 1.21e3.10
LN removed (grouping B) 0.004
1e11 1.00
12 0.59 0.41e0.84
Surgery 0.574
Elective 1.00
Urgent 1.16 0.69e1.96
Adjuvant chemotherapy 0.014
Yes 1.00
No 1.67 1.11e2.51
CI: conﬁdence interval; LN: lymph node.
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threshold was determined as signiﬁcantly better compared to the
survival of patients with less number of lymph nodes removed. The
reported threshold values were 7 [6e8], 9 [9e11], 10 [12], 12
[13e18], 13 [19], 14 [20e22], 17 [23], and 18 [24]. On the other hand,
two population based studies reported these threshold values as 8
[25] and 13 [26]. A review study concluded that at least 12 lymph
nodes need to be removed to determine the lymph node status [27].
Adjuvant chemotherapy is routinely given to node-positive
colorectal cancer patients; however, its use in node-negative pa-
tients is controversial. Some studies observed that in node-negative
patients with less than 12 lymph nodes removed, those receiving
adjuvant chemotherapy have better survival than those not
receiving it [18,28].
In a study comparing node-negative (stage II) colorectal cancer
patients with patients having 1e3 positive lymph nodes, survival
was found to be similar between node-negative patients having
less than 10 lymph nodes removed and patients having 1e3 posi-
tive lymph nodes, and adjuvant chemotherapy was recommended
for these node-negative patients with fewer nodes removed [29]. In
a review it was stated that accurate tumor staging and prevention
of stage migration can only be achieved when at least 12 lymph
nodes are removed by extended lymphadenectomy, and that suf-
ﬁcient adjuvant therapy should be provided for patients with fewer
non-metastatic lymph nodes removed [30].
In a review, it was stated that the log odds of positive lymph
nodes (LODDS; the log of the ratio between the number of positive
lymph nodes and the number of negative lymph nodes) is a func-
tion of the number of negative lymph nodes, whereas lymph node
ratio is a function of the total number of lymph nodes, and lymph
node ratio is not applicable to pN0 patients, whereas LODDS is a
useful lymph node classiﬁcation for pN0 patients because it can
discriminate between subgroups with different survival rates and
minimizes the stage migration phenomenon caused by an insufﬁ-
cient number of retrieved nodes [31].
In conclusion, in colorectal cancer patients whose removed
lymph nodes are non-metastatic, removal of at least 12 lymph
nodes will determine the lymph node status reliably. Patients with
less than 12 lymph nodes removed may beneﬁt from adjuvant
chemotherapy due to the possibility of some metastatic lymph
nodes being left behind.
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